IRCT20211004052664N1招募中3 期
Evaluation of the efficacy of Favipiravir in comparison with standard medication on clinical and laboratory findings of COVID-19 patients with moderate severity
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 14 years 至 no limit（—）
- 性别
- All
入选标准
- •Laboratory covfirmation of COVID-19 virus by RT-PCR or imaging findings consistent with COVID-19
- •Moderate-severity disease (respiratory rate <30 per minute, oxygen saturation > 94% or pulmonaru infiltration < 50% in both lungs)
- •Age above 14 years
- •Willingness to participate in this study
排除标准
- •Immunocompromised patients
- •Consumption of effective drugs in the treatment of COVID-19 in this clinical course
- •History of severe hypersensitivity or anaphylactic shock
研究者
相似试验
招募中
3 期
Evaluation the effects of Favipiravir in COVID-19 patientsCOVID-19 pneumonia.COVID-19, virus identifiedU07.1IRCT20151227025726N14Shahid Beheshti University of Medical Sciences84
已完成
3 期
Favipiravir effectiveness in patients undergoing COVID19 Acute respiratory distress syndrome (ARDS)covid positive.Coronavirus infection, unspecifiedB34.2IRCT20150107020592N26Masih Daneshvari Hospital20
已完成
不适用
Investigation on the effect of favipiravir in preventing Ebola virus disease and its safetyEbola virus diseaseJPRN-UMIN000016102ational Center for Global Health and Medicine25
招募中
3 期
The effects of Favipiravir and Lopinavir/Ritonavir in treatment COVID-19IRCT20200506047323N3Bandare-abbas University of Medical Sciences60
招募中
3 期
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126